The goal of PRTMI is to undertake preclinical and clinical trials in regenerative medicine for delivery of therapies, overcoming delays caused by non-clinical considerations.
PRTMI intends to interface with clinical and preclinical programs in order to identify potential therapies that can be accelerated into clinical studies. It will develop clinical protocols, organise manufacturing of cellular products for clinical use, and monitor compliance of clinical trials conducted by it with government and regulatory bodies.
Additionally, PRTMI will seek to acquire and strategically align itself with proven products in the market place that may provide strategies, when combined with the regenerative medicine therapies being developed by parent firm, Proteonomix. Further, PRTMI will seek to provide a seamless transition between cellular manufacturing laboratories and patient care facilities.